Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $21

Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc.

TNDM

0.00

Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ: TNDM) with a Neutral and raises the price target from $17 to $21.